{"id":"W4405364934","doi":"10.1016/j.msard.2024.106114","title":"153. Efficacy and Safety of Tolebrutinib Versus Placebo in Non-Relapsing Secondary Progressive Multiple Sclerosis: Results From the Phase 3 HERCULES Trial","year":2024,"lang":"en","type":"article","venue":"Multiple Sclerosis and Related Disorders","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Multiple sclerosis; Medicine; Placebo; Relapsing remitting; Internal medicine; Pathology; Immunology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006507599,0.0004464928,0.0007485379,0.0002050856,0.0002937129,0.0001120196,0.0001723246,0.0004008504,0.0001714781],"category_scores_gemma":[0.0007248787,0.0003240313,0.0002270864,0.0005087633,0.0005980095,0.0002791408,0.0001431307,0.0009407832,0.000008784837],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001154683,"about_ca_system_score_gemma":0.0002616915,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001271475,"about_ca_topic_score_gemma":0.0005587736,"domain_scores_codex":[0.996892,0.0002056634,0.001134617,0.0009139643,0.000356285,0.0004974694],"domain_scores_gemma":[0.9964706,0.00253861,0.0002453809,0.0004678232,0.00005701794,0.0002205535],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.371079,0.001118352,0.002665923,0.000279444,0.001248619,0.00004389282,0.01386654,0.0003024188,0.01474262,0.0000229951,0.001830066,0.5928001],"study_design_scores_gemma":[0.8213441,0.002544723,0.1126595,0.006176502,0.0007306149,0.00001050872,0.006372939,0.04254439,0.001336077,0.00004911569,0.005398771,0.0008327758],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9693099,0.02305426,0.00001695668,0.001706084,0.001208516,0.002639126,0.0005814483,0.0001018778,0.001381866],"genre_scores_gemma":[0.9896395,0.009095225,0.0003193617,0.0001353065,0.0001261809,0.00009230773,0.000450757,0.00006664058,0.00007468128],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5919673,"threshold_uncertainty_score":0.9999212,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03891098586633257,"score_gpt":0.2788187953834719,"score_spread":0.2399078095171393,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}